18F-labeled estradiol derivative for targeting estrogen receptor-expressing breast cancer

A novel 17α‑ethinyl‑estradiol-based ER probe [18F]FETE was developed with high molar activity and good in vitro stability. Based on the results of bio-evaluation in normal immature rats and tumor-bearing mice, it might be a promising candidate for specific PET imaging of ER-positive breast cancer.